The metastatic cascade of tumour cells is a sequence of complex events characterised by their growth at the primary site, invasion of surrounding tissues, penetration into vasculature and transport to distant sites and implantation and formation of secondary lesions. The haematogenous phase of metastasis involved a variety of cell-cell and cell-ECM interactions. Tumour cell interaction with endothelium and ECM, a process believed to determine organ-specific metastasis, is mediated by a wide spectrum of cell-surface adhesion molecules, including integrin receptors (Honn et al., 1992a, b) . There is evidence that systemic or local activation of blood coagulation promotes metastasis, whereas inhibition of the blood clotting cascade favours the host and diminishes metastatic spread (Honn and Sloane, 1984) . However, the exact nature of this association and its potential practical significance are not yet completely understood.
It has been known for over a century that most cancer patients manifest laboratory signs of hypercoagulability and some develop thromboembolic disease (Rickles et al., 1992) .
Clinical trials of anticoagulants or fibrinolytic agents have exhibited improvements in the incidence of tumour regression and in overall survival (Zacharski et al., 1992a) . Therefore, the mainstream of clinical and basic investigators has focused on the role of interactions between tumour cells and the host coagulation system. In certain tumour types, in situ fibrin, the final product of blood coagulation, is present predominantly at the host -tumour interface in abundant amounts (Zacharski et al., 1992b) . Fibrin deposited at the primary site constitutes a component of tumour stroma, which protects tumour cells against cells of the host defence system and facilitates tumour angiogenesis (Zacharski et al., 1992b; Costantini and Zacharski, 1993) . Thrombin, a pluripotent bioregulatory serine proteinase, was reported to enhance the metastatic phenotype of mammary tumour cells by increasing their proliferative response (Medrano et al., 1987) and was also found to be a potent mitogen for tumour cells (Bruhn and Zurborn, 1983) . In fact, in our previous study (Chiang et al., 1994a) , thrombin was shown to mediate SW-480 tumour cell-induced platelet aggregation (TCIPA), which might be important for successful metastasis to occur (Cavanaugh et al., 1988) .
In recent years, purified antiplatelet components from snake venoms, including trigramin-like antiplatelet peptides (Huang et al., 1987a (Huang et al., , 1991a Rucinski et al., 1990; Shebuski et al., 1989) have been widely studied. Trigramin, an ArgGly-Asp (RGD)-containing peptide purified from venom of the snake Trimeresurus gramineus, is a specific antagonist of platelet membrane glycoprotein IIb/IIIa (Huang et al., 1987a (Huang et al., , 1989 . Rhodostomin, an RGD-containing peptide purified from the venom of the Malayan pit viper, Agkistrodon rhodostoma, likewise directly impairs fibrinogen interaction with its specific receptor associated with glycoprotein IIb/IIIa (Huang et al., 1987b (Huang et al., , 1990 . These trigramin-like peptides all contain an RGD epitope, are rich in cysteine and bind with high affinity to the surface of platelets.
The present study documents the effect of thrombin treatment with SW-480 human colon adenocarcinoma cells on regulation of their surface integrin expression, cell adhesive and migratory properties. Rhodostomin was found to strongly inhibit thrombin-enhanced tumour cell adhesion and migration. We also compared the effect of MAbs and synthetic peptide RGDS.
described (Huang et al., 1990 Chopra et al., 1988) . MAb against f,3 integrin (MAB1977) was obtained from Chemicon, CA, USA MCA698 (anti-X5fi) and MCA699 (anti-C461,) were purchased from Serotec, Bicester, UK.
Methods
Cell culture SW-480 human colon adenocarcinoma cells were grown in 95% air-5% carbon dioxide in Dulbecco's modified Eagle medium (DMEM) tissue culture medium supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM glutamine, penicillin (100 U ml-') and streptomycin (100 pg ml-'). Cells were passed and harvested for experiments before reaching confluence. Human umbilical vein endothelial cells (HUVECs) were prepared as described by Jaffe et al, (1973) . Umbilical cord veins were cannulated and flushed with cord buffer to remove blood and then filled with 0.1% collagenase solution (type I, Sigma) for 15-20 min at 37°C. Detached cells were recovered by flushing with M199 and collected by centrifugation at 1000 r.p.m. for 5 min. The cells were then suspended in M199 containing 20% FCS, penicillin (100 U ml-') and streptomycin (100 pg ml-') before seeding. After 18-24 h incubation the medium was removed, the cells washed gently before fresh medium was added. Cell migration assays Cell migration assays were carried out in millicell-PCF inserts (Millipore) by using standard 24-well tissue culture plates (Costar, USA). Briefly, SW-480 cells were harvested and incubated with BCECF-AM as previously described (Chiang et al., 1994b) . The fluorescence-loaded cells were then resuspended in DMEM without serum and preincubated with buffer or thrombin (0.5 U ml-') for 30 min at 370C, followed by washing and addition of either buffer or 3.5 pg ml-' rhodostomin before migration assays. They were added (3 x 105 cells ml-') to the upper compartment of a millicell-PCF insert and the lower compartment was filled with medium containing a chemoattractant: fibronectin (30 pg ml-') and control medium (serum-free DMEM containing 0.1% bovine serum albumin). The two compartments of the millicell-PCF inserts were separated by a polycarbonate filter (12 pm pore size) precoated with gelatin (5 pg ml-1, Sigma). SW-480 cells were allowed to migrate for 14 h at 37°C in a humidified atmosphere containing 5% carbon dioxide. Cells on the upper side of the filter were removed mechanically, and the adherent cells on the lower side of the filter were read with a CytoFluor 2300 fluorescence plate reader (Millipore Corp.) as described in cell adhesion assays.
Flow cytometric analysis Flow cytometric studies were performed to quantify surface expression of integrins (Chiang et al., 1994b) . SW-480 cells were detached (using 0.5 mM EDTA), washed and then stimulated with 0.5 U ml-' thrombin at 37°C for 30 min in 500 p1 of PBS containing 106 cells per sample. Following washing the cells were fixed with 2.7% paraformaldehyde for 10 min, blocked with normal goat serum (1:2) for 25 min, and labelled with MAbs (20 pg ml-') for 1 h. After washing cells were relabelled with goat anti-mouse IgG-FITC. FITC signals were detected and digitised in logarithmic configuration and the data collected on a EPICS computer system. Data were collected in 256-channel resolution and 10 000 cells were counted per experimental group. Fluorescence intensity was directly proportional to the fluorescein label present on the tumour cell surface. All experiments were repeated at least four times.
Results
Effect of thrombin on SW-480 tumour cell adhesion to human endothelial cells In this study we showed that SW-480 human colon adenocarcinoma cells respond to human thrombin by increased adhesion to human endothelial cell monolayers, HMVEC and HUVEC. We used different concentrations of thrombin, ranging from 0.01 to 5 U ml-' with incubation time of 30 min. Figure la shows that stimulation of SW-480 cells with various concentrations of thrombin exhibited bellshaped dose -response curves in increasing adhesion to endothelial cells (ECs) with a peak at 0.5 U ml-'. The maximal effects for HUVEC and HMVEC were approximately 3.5-and 2.3-fold increases respectively in the number of adherent cells. Both increments were significant effects (P<0.001). A concentration of thrombin as low as 0.01 U ml-' enhanced adhesion, whereas higher concentrations (i.e. 5 U ml-') were ineffective.
Effect of thrombin on SW-480 tumour cell adhesion to fibronectin Fibronectin (FN), which is found in the fibro-connective tissue stoma, was also used as a substratum for studies of SW-480 cell-adhesion. Thrombin treatment resulted in a maximal response of approximately 2.5-fold increase in the number of adherent cells. The dose-response curve was also bell-shaped, with the maximal effect at 0.5 U ml-' ( Figure  la) . However, similar to the results from adhesion to ECs, subclotting concentrations of thrombin (i.e., 0.01 U ml-') also enhanced adhesion whereas higher concentrations (i.e., 5 U ml-') did not. Incubation of SW-480 cells with thrombin for different time periods also revealed a bell-shaped pattern (Figure lb) . A slight increase was observed 5 min after pretreatment with thrombin and the optimal response occurred when tumour cells were stimulated with thrombin for a period ranging between 30 min and 4 h. Prolonged incubation of tumour cells (8-24 h) with thrombin resulted in a decrease in tumour cell adhesion.
When thrombin was mixed with hirudin, a specific thrombin inhibitor, a profound inhibition was found compared with the buffer control ( Figure 2 ). This suggests that an intact thrombin molecule is apparently required to enhance SW-480 cell adhesion. In addition, an irreversible serine protease inhibitor, 3,4-DCI, was observed to completely block thrombin-enhanced adhesion of SW-480 cells to FN, further suggesting that the active site serine residue is required for the enhancing effect of thrombin. Incubation with thrombin (time) (Figure 3a) , a potent but relatively less selective PKC inhibitor, or calphostin C (Figure 3b) However, in all cases, adhesion was reduced to basal levels by pretreatment with 7E3 (30 ,ug ml-'), an MAb that recognises an antigenic determinant on the P subunit of GpIIb/IIIa (i.e. GpIIIa) (Chopra et al., 1988) , suggesting that /l3 integrins played an important role in thrombin-enhanced SW-480 cell adhesion. Rhodostomin, an RGD-containing peptide, potently blocked the SW-480 cell adhesion response to thrombin at a concentration of 2.3 Mg ml-' (0.3 juM). The synthetic peptide RGDS had a similar inhibition with the maximal effect at 75 Mg ml-' (176 gM). On a molar basis, therefore, rhodostomin is about 600 times more potent than RGDS in inhibiting thrombin-enhanced adhesion.
Effect of rhodostomin on thrombin-enhanced SW-480 tumour cell migration The migratory activity of SW-480 cells was assayed in millicell-PCF inserts by using 24-well plates as described in Materials and methods. As shown in Figure Finally, these cells were washed once, resuspended and allowed to adhere to fibronectin-coated plates for 60 min at 370C. TPA (0.1,IM, 37°C for 5min) was used as a positive control for PKC activation, as we previously reported (Chiang et al., 1994b in Materials and methods. As shown in Figure 6a and b, thrombin-stimulated cells exhibited an increase in the number of cells positively stained for P3 integrins and an enhanced fluorescence. Figure 6c shows the quantitative results of P3
integrin expression on SW-480 cells stimulated by thrombin, indicating that both mean fluorescence intensity and the mean number of positively staining cells were significantly increased. However, cells probed first with MAbs MAB1977
(anti-PlI integrin), MCA698 (anti-x5#,1) or MCA699 (anti-CX60,)
did not show a significant increase in fluorescence intensity in response to thrombin pretreatment (data not shown).
Discussion
Rhodostomin, an RGD-containing disintegrin, has been demonstrated to directly impair fibrinogen interaction with its specific receptor associated with GP IIb/IIIa (Huang et al., 1987b (Huang et al., , 1990 . We previously showed that rhodostomin is about 18 000 times more potent that the synthetic peptide GRGDS in inhibiting SW-480 TCIPA, a thrombin-dependent reaction owing to SW-480 tissue factor activity expression, by virtue of its antiplatelet activity (Chiang et al., 1994a) . We also reported that rhodostomin binds via its RGD sequence to multiple integrin receptors (i.e. aIIbMP3, c,#39, cL5f,) expressed on the SW-480 cell surface, and thereby blocks the adhesion of SW-480 cells to ECM (Chiang et al., 1994b) . In the present study, rhodostomin was further shown to significantly block thrombin-enhanced adhesion and migration of SW-480 cells, the two major events determining the tumour metastasis potential. Rhodostomin was about 600 and 500 times more potent than RGDS in inhibiting thrombin-enhanced SW-480 cell adhesion and migration respectively. Activation of blood coagulation, a common feature in cancer patients, leads to the generation of thrombin. The biological effect of thrombin, as well as its role in TCIPA and fibrin formation may favour the metastatic spread of cancer by promoting cell migration, mediating tumour cell adhesion, stimulating autocrine growth factor secretion or inducing neovascularisation (Costantini and Zacharski, 1993; Wojtukiewicz et al., 1992; Zacharski et al., 1990) . In the present study, thrombin was found to enhance SW-480 tumour cell adhesion and migration with the optimal concentration of 0.5 U ml-'. According to a previous study, during clotting of whole blood or plasma, only approximately 15 U ml-' v thrombin is ever measurable, despite more than 80% consumption of prothrombin (Fenton, 1988 (Fenton, 1988) . Thus, tumour cells entrapped in the fibrin clot may be under a constant stimulation by thrombin and become more predisposed to successful metastasis. The optimal effectiveness of low concentrations of thrombin for enhanced adhesion and migration suggests a thrombin-receptor-mediated mode of action. At present, there are two major thrombin receptors reported. Glycoprotein lb (GP Tb), the predominant thrombin-binding molecule on human platelets, was implicated in both high-and moderate-affinity pathways of platelet activation (Greco and Jamieson, 1991) . In our study, thrombin-enhanced adhesion was not significantly affected by pretreatment of SW-480 cells with AP, (25 jug ml-'), the MAb of GP lb (data not shown), indicating that the enhanced adhesion did not result from the binding of thrombin to GP lb on tumour cells. The other candidate is a high-affinity functional thrombin receptor, a member of the superfamily of seven-pass transmembrane proteins (Vu et al., 1991 Our study on thrombin-enhanced SW-480 tumour cell adhesion to both ECs and FN revealed a bell-shaped doseresponse curve. No stimulatory effect was observed when tumour cells were incubated with higher doses (i.e. 5 U ml-') of thrombin. At present, a precise interpretation of this dose dependency of the thrombin effect is unknown. One possibility is that thrombin-elicited effects on adhesion (probably through binding to its high-affinity receptors on tumour cells) are down-regulated (or desensitised) at high doses of agonist, a phenomenon that is characteristic of most G-protein-linked reactions (Greco and Jamieson, 1991; Wojtukiewicz et al., 1993; Manning and Brass, 1991 Likewise, PKC has been suggested to be involved in mediating the cellular effects of thrombin (Gomez et al., 1988; di Corleto and de la Motte, 1989) . Therefore, we used the non-selective but potent protein kinase inhibitor, staurosporine, and the selective inhibitor of PKC, calphostin C, to examine the effect of thrombin. Calphostin C markedly prevented thrombin-enhanced adhesion, which is similar to the effect of staurosporine. This indicates that thrombinelicited effects probably operate via PKC activation.
In our study, thrombin challenge of human colon adenocarcinoma cells up-regulates cell-surface expression of /3 integrins, which promote the migration and adhesion of tumour cells to FN and ECs. Because the interactions of tumour cells with platelets and plasma components generate thrombin and some lipoxygenase metabolite of arachidonic acid (i.e. the thrombin-dependent TCIPA owing to tissue factor activity expression on SW-480 cells), which may potentiate metastatic ability, our serial studies implied that if a significant number of colon adenocarcinoma cells induced TCIPA followed by thrombin-enhanced metastasis process, PKC inhibitors as well as integrin receptor antagonists (particularly the potent Arg-Gly-Asp-containing venom peptide, rhodostomin) might be considered as possible adjuvant therapeutic agents in the prevention of certain cancer metastasis. Further studies are being undertaken to explore the antimetastatic effect of rhodostomin on the metastasis of SW-480 cells in experimental animals.
